logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 8940688 B1

PDFFull Text
Date of Patent:
Jan. 27, 2015

Filed:

Dec. 04, 2008

Fluorinated tripeptide hcv serine protease inhibitors

Applicants:

Yonghua Gai, North Grafton, MA (US);

Yat Sun OR, Watertown, MA (US);

Zhe Wang, Hockessin, DE;

Inventors:

Yonghua Gai, North Grafton, MA (US);

Yat Sun Or, Watertown, MA (US);

Zhe Wang, Hockessin, DE;

Assignee:

Enanta Pharmaceuticals, Inc., Watertown, MA (US);

Attorneys:

Edger W. Harlen

Carolyn S. Elmore, Esq.

Elmore Patent Law Group, P.C.

Primary Examiner:

Thomas S Heard

Int. Cl.
CPC ...
A61K 38/00 (2006.01); C07D 401/12 (2006.01); C07D 403/12 (2006.01); C07D 207/16 (2006.01); C07D 417/14 (2006.01); C07D 403/14 (2006.01); C07D 403/04 (2006.01); C07D 409/14 (2006.01); C07D 417/12 (2006.01); C07D 405/12 (2006.01); C07D 413/12 (2006.01); C07D 409/12 (2006.01); C07D 413/14 (2006.01); C07D 471/04 (2006.01); C07K 5/10 (2006.01);
U.S. Cl.
CPC ...
C07D 403/12 (2013.01); C07D 401/12 (2013.01); C07D 207/16 (2013.01); C07D 417/14 (2013.01); C07D 403/14 (2013.01); C07D 403/04 (2013.01); C07D 409/14 (2013.01); C07D 417/12 (2013.01); C07D 405/12 (2013.01); C07D 413/12 (2013.01); C07D 409/12 (2013.01); C07D 413/14 (2013.01); C07D 471/04 (2013.01); C07K 5/1027 (2013.01);
Abstract

The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Find Patent Forward Citations

Loading…